HCA Healthcare (HCA) CEO reports 54,934-share performance stock vesting
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
HCA Healthcare CEO Samuel N. Hazen reported equity transactions in company common stock. On February 10, 2026, he acquired 54,934 shares at $0 per share as a grant tied to performance share units that fully vested at 200% of the original award.
On the same date, 21,323 shares were disposed of at $502.05 per share to satisfy tax withholding obligations, leaving 64,842 shares held directly. He also reports indirect ownership, including 200,000 shares held by a 2025 GRAT and 813,320 shares held by an LP.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
HAZEN SAMUEL N
Role
CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 54,934 | $0.00 | -- |
| Tax Withholding | Common Stock | 21,323 | $502.05 | $10.71M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 86,165 shares (Direct);
Common Stock — 16,024 shares (Indirect, By HD Trust)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did HCA (HCA) CEO Samuel Hazen report?
HCA CEO Samuel Hazen reported a grant of 54,934 shares of common stock on February 10, 2026. The shares came from performance share units that vested based on 2023-2025 earnings per share performance, resulting in a 200% payout versus the original 27,467-unit grant.